Breast Cancer

Tiffany Traina MD and Sara Hurvitz MD review data from key breast cancer presentations at the 2016 American Society of Clinical Oncology Annual Meeting.

Share

Program Content

Activities

  • Practice-Changing Data in Breast Cancer
    Breast Cancer: A Look Ahead to Practice-Changing Data at the 2016 Clinical Oncology Meeting
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 31, 2016

    Expires: May 30, 2017

  • Breast Cancer Resection
    Phase III MF07-01 Trial: Impact of Initial Local Resection on Stage IV Breast Cancer Survival
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • Abemaciclib Active in HR+ MBC
    Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC After Chemotherapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • T-DM1 + P vs TCH + P in HER2+ EBC
    KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab + Pertuzumab in HER2+ EBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 06, 2016

    Expires: June 05, 2017

  • MA.17R: Benefit of Extended Letrozole
    MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2016

    Expires: June 06, 2017

  • Atezolizumab in mTNBC
    Atezolizumab + Nab-Paclitaxel Well Tolerated and Active in Metastatic TNBC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2016

    Expires: June 06, 2017

  • TC vs TaxAC in HER2- EBC
    ABC Trials Joint Analysis: TC vs TaxAC in High-Risk, HER2-Negative Early Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 07, 2016

    Expires: June 06, 2017

  • Second-line Pertuzumab in HER2+ MBC
    PHEREXA: No PFS Benefit of Adding Pertuzumab to Trastuzumab + Capecitabine in HER2+ MBC Progressing on or After Trastuzumab-Based Therapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 09, 2016

    Expires: June 08, 2017

  • Palbociclib in ER+ Breast Cancer
    PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 14, 2016

    Expires: June 13, 2017

  • Downloadable Slideset
    Breast Cancer: A Review of Key Clinical Studies
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: August 16, 2016

    Expires: August 15, 2017

Faculty

cover img faculity

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals